文献速递临床试验与 GCP

高流量鼻导管治疗对心脏术后肺部并发症高风险患者以患者为中心结局的影响:多中心适应性随机对照试验NOTACS的统计分析计划更新

Effect of high-flow nasal therapy on patient-centred outcomes in patients at high risk of postoperative pulmonary complications after cardiac surgery: update to the statistical analysis plan for NOTACS, a multicentre adaptive randomised controlled trial.
PubMed 文献 · Trials · 2024-11-06

NOTACS是一项多中心适应性随机对照试验,比较高流量鼻导管治疗(HFNT)与标准氧疗(SOT)对心脏术后患者结局的有效性、安全性和成本效果。计划至少纳入850例患者,主要结局为术后90天内存活且在家天数(DAH90),中期样本量再估计可在至少300例随访90天后将样本量增至最多1280例。

要点

  • NOTACS试验比较HFNT与SOT对心脏术后患者以患者为中心结局的影响。
  • 主要结局为术后90天内存活且在家天数(DAH90)。
  • 计划至少随机850例,中期样本量再估计可增至最多1280例。

核心结论

  • 本文提供NOTACS试验设计及中期和最终分析的详细描述,以在适应性设计框架下保持科学完整性。

研究设计与样本

  • NOTACS是一项适应性、国际、多中心、平行组随机对照试验,预设中期样本量再估计(SSR)。
  • 计划至少850例患者按1:1随机接受HFNT或SOT。
  • 中期SSR在至少300例患者随访90天后进行,样本量最多可增至1280例。

关键数值与推荐

  • 主要结局为计划手术后90天内存活且在家天数(DAH90)。
  • 还计划进行多项次要分析和成本效果分析。
  • 中期分析主要目的是评估安全性和进行样本量再估计;最终分析主要目的是评估HFNT与SOT相比的安全性、有效性和成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The NOTACS trial will assess the efficacy, safety and cost-effectiveness of high-flow nasal therapy (HFNT) compared to standard oxygen therapy (SOT) on the outcomes of patients after cardiac surgery. METHODS/DESIGN: NOTACS is an adaptive, international, multicentre, parallel group, randomised controlled trial, with a pre-planned interim sample size re-estimation (SSR). A minimum of 850 patients will be randomised 1:1 to receive either HFNT or SOT. The primary outcome is days alive and at home in the first 90 days after the planned surgery (DAH90), with a number of secondary analyses and cost-effectiveness analyses also planned. The interim SSR will take place after a minimum of 300 patients have been followed up for 90 days and will allow for the sample size to increase up to a maximum of 1280 patients. RESULTS: This manuscript provides detailed descriptions of the design of the NOTACS trial and the analyses to be undertaken at the interim and final analyses. The main purpose of the interim analysis is to assess safety and to perform a sample size re-estimation. The main purpose of the final analysis is to examine the safety, efficacy and cost-effectiveness of HFNT compared to SOT on the outcomes of patients after cardiac surgery. DISCUSSION: This manuscript outlines the key features of the NOTACS statistical analysis plan and was submitted to the journal before the final analysis in order to preserve scientific integrity under an adaptive design framework. A previous version of this SAP was published prior to the interim analysis (Dawson, 2022). The NOTACS SAP closely follows published guidelines for the content of SAPs in clinical trials (Gamble, 2017). TRIAL REGISTRATION: ISRCTN14092678 . (13 May 2020).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dawson SN, Chiu YD, Klein AA, et al. Effect of high-flow nasal therapy on patient-centred outcomes in patients at high risk of postoperative pulmonary complications after cardiac surgery: update to the statistical analysis plan for NOTACS, a multicentre adaptive randomised controlled trial. Trials. 2024. PMID: 39506858. doi:10.1186/s13063-024-08538-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。